Revolution Medicines (NASDAQ:RVMD) Price Target Raised to $241.00

Revolution Medicines (NASDAQ:RVMD) had its price objective boosted by Truist Financial from $240.00 to $241.00 in a research report report published on Monday morning, Marketbeat.com reports. Truist Financial currently has a buy rating on the stock.

Several other equities research analysts have also recently issued reports on the stock. Stifel Nicolaus boosted their price objective on shares of Revolution Medicines from $215.00 to $230.00 and gave the company a “buy” rating in a research report on Wednesday, September 9th. Wolfe Research restated an “outperform” rating and issued a $220.00 target price on shares of Revolution Medicines in a research note on Monday, August 10th. Sanford C. Bernstein raised their target price on shares of Revolution Medicines from $151.00 to $179.00 and gave the stock a “market perform” rating in a research report on Friday, August 21st. Needham & Company LLC reaffirmed a “buy” rating and set a $275.00 target price on shares of Revolution Medicines in a research report on Thursday, October 15th. Finally, Oppenheimer lifted their price target on shares of Revolution Medicines from $230.00 to $260.00 and gave the company an “outperform” rating in a research note on Thursday, August 27th. One equities research analyst has rated the stock with a Strong Buy rating, twenty-two have assigned a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $242.95.

Revolution Medicines Stock Down 1.2%

NASDAQ RVMD opened at $194.28 on Monday. The company’s 50-day moving average price is $202.32 and its 200-day moving average price is $175.95. The company has a debt-to-equity ratio of 0.40, a quick ratio of 11.38 and a current ratio of 11.38. Revolution Medicines has a 12 month low of $52.48 and a 12 month high of $224.31.

Revolution Medicines (NASDAQ:RVMD) last posted its quarterly earnings results on Wednesday, August 5th. The company reported ($3.06) EPS for the quarter, missing the consensus estimate of ($2.04) by ($1.02). During the same period in the prior year, the firm earned ($1.31) EPS. As a group, sell-side analysts expect that Revolution Medicines will post -8.93 earnings per share for the current year.

Insider Activity

In other news, insider Alan Sandler sold 6,309 shares of the firm’s stock in a transaction on Tuesday, September 29th. The stock was sold at an average price of $202.14, for a total transaction of $1,275,301.26. Following the transaction, the insider owned 52,559 shares in the company, valued at approximately $10,624,276.26. This trade represents a 10.72% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, insider Mark Goldsmith sold 80,000 shares of Revolution Medicines stock in a transaction dated Friday, August 21st. The shares were sold at an average price of $209.20, for a total value of $16,736,000.00. Following the completion of the sale, the insider owned 267,330 shares of the company’s stock, valued at $55,925,436. The trade was a 23.03% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last 90 days, insiders have sold 290,991 shares of company stock valued at $59,422,765. Company insiders own 7.60% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Alphabet Inc. purchased a new position in Revolution Medicines during the 2nd quarter valued at about $551,843,000. Assenagon Asset Management S.A. raised its holdings in shares of Revolution Medicines by 987.9% in the 3rd quarter. Assenagon Asset Management S.A. now owns 2,181,185 shares of the company’s stock valued at $447,710,000 after purchasing an additional 1,980,699 shares in the last quarter. Bank of America Corp DE purchased a new stake in shares of Revolution Medicines in the 2nd quarter worth approximately $184,267,000. Deutsche Bank AG purchased a new stake in shares of Revolution Medicines in the 2nd quarter worth approximately $166,308,000. Finally, Bank of New York Mellon Corp purchased a new stake in shares of Revolution Medicines in the 2nd quarter worth approximately $112,566,000. 94.34% of the stock is currently owned by institutional investors.

Key Headlines Impacting Revolution Medicines

Here are the key news stories impacting Revolution Medicines this week:

• Positive Sentiment: Phase 3 trial advanced: Revolution Medicines began treating patients in the RASolve 308 trial, evaluating investigational zoldonrasib alongside pembrolizumab and chemotherapy as a first-line treatment for metastatic RAS G12D non-squamous non-small cell lung cancer. Starting a pivotal trial represents progress toward a potential registration-supporting data set and expands the drug’s commercial opportunity. Revolution Medicines Begins Treating Patients in Phase 3 RASolve 308 Trial
• Positive Sentiment: Analyst support remains strong: TD Cowen reaffirmed its “Buy” rating and set a $250 price target, while Brookline Capital Markets maintained a “Buy” rating with a $318 target. Truist Financial also indicated that RVMD’s stock is expected to rise. These targets imply considerable upside based on the referenced trading level. Truist Financial Analyst Expects Revolution Medicines Stock to Rise
• Positive Sentiment: Broader biotech momentum: RVMD was among biotech stocks that advanced during a sector-wide move higher, suggesting favorable industry sentiment also contributed to recent trading interest. Biotech Stocks Move Higher
• Neutral Sentiment: Third-quarter results scheduled: Revolution Medicines will report its third-quarter 2026 financial results after the market closes on November 4, followed by a management webcast. The update may provide new information on cash resources, development spending and clinical progress.
• Neutral Sentiment: Losses remain expected: Brookline projects third-quarter EPS of negative $2.36 and fourth-quarter EPS of negative $1.94, compared with a consensus full-year estimate of negative $8.93. Continued losses are typical for a development-stage biotechnology company but leave RVMD sensitive to earnings, cash-burn and pipeline updates.

About Revolution Medicines

Revolution Medicines, Inc is a clinical-stage biopharmaceutical company focused on developing targeted therapies for patients with RAS-mutant cancers. The company’s research platform is designed to discover and develop medicines that inhibit RAS proteins, which play a central role in the growth and spread of many cancers and have historically been difficult to target.

Its investigational pipeline includes RAS(ON) inhibitors and other precision oncology candidates, including daraxonrasib (RMC-6236), a pan-RAS inhibitor being evaluated in multiple solid tumors, as well as programs directed at specific mutations such as KRAS G12C and KRAS G12D.